跳至主要内容
临床试验/TCTR20200814001
TCTR20200814001已完成3 期

Oligonol and its beneficial effects in non-alcoholic fatty liver disease

AHCC (Thailand) co. Ltd.0 个研究点目标入组 40 人开始时间: 2020年8月14日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 0 N/A (No limit)(—)
性别
All

入选标准

  • •Adults aged 18 years and older with NAFLD were enrolled in the study. NAFLD was defined by elevated ALT (ALT ≥19 U/L in women and ≥30 U/L in men) with the presence of hepatic steatosis grade ≥2 (defined as liver fat content ≥11% by MRI-PDFF).

排除标准

  • •(1) cirrhosis defined by cirrhotic configuration on liver imaging or liver stiffness score ≥ 10.3 kPa on transient elastography
  • •(2) liver decompensation (defined by history of bleeding varices, ascites, and encephalopathy)
  • •(3) hepatocellular carcinoma
  • •(4) daily alcohol drinking >30 g in men, 20 g in women
  • •(5) other known chronic liver diseases, such as chronic hepatitis B, chronic hepatitis C, autoimmune hepatitis, primary biliary cholangitis, hemochromatosis, and Wilson disease
  • •(6) pregnancy
  • •(7) history of lychee allergy
  • •(8) chronic kidney disease stage 3 and above (calculated glomerular filtration rate <60 mL/min).

研究者

发起方
AHCC (Thailand) co. Ltd.

相似试验